Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has received an average rating of “Hold” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating and nine have issued a hold rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.44.

A number of brokerages recently issued reports on MNTA. Stifel Nicolaus reissued a “hold” rating and issued a $15.00 price objective (down from $22.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, October 4th. Zacks Investment Research lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Barclays reissued an “equal weight” rating and issued a $16.00 price objective (down from $17.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and issued a $14.00 price objective (down from $18.00) on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Finally, Cowen set a $15.00 price objective on Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 1st.

In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.35, for a total value of $54,948.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total value of $678,743.01. Following the completion of the sale, the president now owns 286,121 shares of the company’s stock, valued at $5,444,882.63. The disclosure for this sale can be found here. Insiders sold 44,006 shares of company stock valued at $789,369 over the last 90 days. 4.40% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. lifted its position in shares of Momenta Pharmaceuticals by 14.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 834 shares during the last quarter. Pinebridge Investments L.P. lifted its position in shares of Momenta Pharmaceuticals by 4.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 363 shares during the last quarter. Profund Advisors LLC lifted its position in shares of Momenta Pharmaceuticals by 13.1% during the 2nd quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 1,530 shares during the last quarter. Citigroup Inc. lifted its position in shares of Momenta Pharmaceuticals by 263.2% during the 2nd quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock valued at $232,000 after acquiring an additional 9,954 shares during the last quarter. Finally, Piedmont Investment Advisors LLC acquired a new stake in shares of Momenta Pharmaceuticals during the 2nd quarter valued at $244,000. Hedge funds and other institutional investors own 93.45% of the company’s stock.

Momenta Pharmaceuticals (NASDAQ:MNTA) opened at $13.35 on Thursday. Momenta Pharmaceuticals has a fifty-two week low of $11.85 and a fifty-two week high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. The company had revenue of $24.09 million during the quarter, compared to analyst estimates of $29.58 million. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The business’s revenue was down 17.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.26) earnings per share. analysts expect that Momenta Pharmaceuticals will post -1.16 EPS for the current year.

WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Given Average Rating of “Hold” by Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/14/momenta-pharmaceuticals-inc-mnta-given-average-rating-of-hold-by-analysts.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.